Market Context — Why This Technology, Why Now

The biotechnology sector is experiencing unprecedented growth, fueled by advancements in genetic engineering and increasing consumer demand for sustainable and bio-derived products. Companies are under pressure to innovate faster, reduce production costs, and ensure supply chain resilience for high-value proteins and advanced materials. This technology offers a compelling solution by leveraging silkworms as a robust, scalable, and environmentally conscious bioreactor, aligning with global trends towards bio-economy and circular manufacturing.

Key Competitive Advantages
01

Reduces production steps by up to 30% by simplifying complex gene introduction processes, cutting workload and time costs.

02

Improves post-gene introduction hatching rate to over 90% by crossing specific silkworm strains, dramatically boosting production efficiency.

03

Ensures stable maintenance and propagation of genetically modified strains, providing consistent quality and supply stability.

Market Opportunity
Pharmaceuticals and Regenerative Medicine
$3B–$4B globally (AI est.)
The utilization of silkworms as an efficient production platform for high-function proteins, such as vaccines, antibody drugs, and growth factors, is expanding and could drive significant market growth in this sector.
Biopharmaceutical companies developing novel protein therapeutics Contract Development and Manufacturing Organizations (CDMOs) for biologics Research institutions focused on regenerative medicine materials
Functional Foods and Cosmetics
$1B–$2B globally (AI est.)
Producing specific functional peptides or beauty ingredients like collagen using silkworms could enable the development of high-quality, lower-cost products, enhancing market competitiveness in this segment.
Nutraceutical manufacturers seeking novel protein sources Cosmetic brands developing bio-derived ingredients Food ingredient suppliers focused on sustainable production
Advanced Biomaterial Development
$1.5B–$2.5B globally (AI est.)
Development of new silkworm-derived materials, such as artificial silk, medical sutures, and biodegradable plastics, is advancing. These solutions are gaining attention for combining high functionality with reduced environmental impact.
Medical device manufacturers seeking biocompatible materials Textile and apparel companies developing sustainable fibers Chemical companies exploring bio-based polymers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a comprehensive process for producing genetically modified cloned silkworms, encompassing the crossing of specific silkworm strains through to the creation of clones. The patent successfully navigated a rejection notice with a well-reasoned response, indicating a robust and thoroughly examined scope of protection.

Competitive White Space

This patent primarily covers the method of producing genetically modified cloned silkworms. Adjacent white space includes novel genetic constructs for specific protein expression, advanced bioreactor designs for silkworm rearing, and downstream processing techniques for extracted biomaterials.

Economic Impact
~$800K/year estimated production cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Conventional genetically modified silkworm production incurs an estimated annual cost of ~$1.5M (AI est.) from low hatching rates, material loss, and high labor/equipment expenses due to multiple steps. This technology improves hatching rates from 50% to over 90% and reduces process steps by 30%, leading to an estimated 60% overall improvement in material loss and labor time. This translates to an estimated annual cost reduction of ~$800K (AI est.), in addition to reduced opportunity costs from improved production efficiency.

Speed to Market
4× faster than in-house development
This technology is based on established protocols from a national R&D institution. Since fundamental research, principle verification, and initial optimization are complete, adopting companies can expect significantly reduced development timelines compared to in-house development from scratch. Key technical challenges in gene introduction and clone production are already resolved, potentially allowing licensees to establish production systems quickly and shorten time-to-market by approximately 3 years.
Competitive Positioning

X: Development & Production Efficiency
Y: Production Stability & Quality Uniformity

Business Models & Applications
📝 Licensing Model
Granting implementation rights to specific companies in exchange for royalty income. Licensees can integrate this technology with existing production facilities to develop new products and enhance production efficiency.
🤝 Joint Development & Contract Manufacturing Model
Collaborating with licensees on R&D for specific protein or material production. This could also involve offering contract manufacturing services utilizing the technology to establish new revenue streams.
🧪 High-Function Material & Pharmaceutical Raw Material Sales Model
Directly selling high-function proteins or materials derived from genetically modified silkworms produced with this technology to pharmaceutical, food, or cosmetic manufacturers as high-value-added products.
Adjacent Application Opportunities
💊 Pharmaceutical Development
Next-Generation Vaccine & Antibody Drug Production
This technology could enable silkworms to be used as bioreactors for low-cost, large-scale production of active ingredients for influenza vaccines and antibody drugs. It offers potential for expanding production scale and rapidly establishing supply systems compared to traditional cell culture, addressing a global market worth over $3.5B (AI est.).
🧬 Biomaterials & Chemicals
High-Performance Silk & Biocompatible Materials
By introducing specific genes, silkworms could produce high-performance silk with superior strength, elasticity, and biocompatibility, as well as materials for medical implants and regenerative medicine scaffolds. This addresses a growing demand for eco-friendly, advanced materials in a market exceeding $2B (AI est.).
🍎 Functional Foods & Supplements
Nutrient-Enhanced Silkworm-Derived Foods
Developing silkworms enhanced with specific nutrients like vitamins, amino acids, or antioxidants could provide raw materials for health foods and supplements. This offers potential for allergy-friendly or novel food products, targeting a functional food market valued at over $1.5B (AI est.).
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Technology Validation & Protocol Optimization
Duration: 4 months
Evaluate compatibility with the licensee's specific production goals and existing facilities, then optimize the gene introduction protocol and silkworm strain selection for this technology. Conduct a small-scale Proof of Concept (PoC) to acquire baseline data.
Phase 2: Pilot Production & Quality Assessment
Duration: 9 months
Initiate pilot-scale production of genetically modified cloned silkworms based on the optimized protocol. Thoroughly evaluate the quality, safety, and functionality of produced proteins or materials, identifying and resolving issues for full-scale implementation.
Phase 3: Full-Scale Implementation & Mass Production Setup
Duration: 9 months
Leverage insights from pilot production to implement the technology into production lines and establish a mass production system. Maximize cost efficiency and production stability, then commence product supply to the market. Maintain competitiveness through continuous improvement.
Technical Feasibility
This technology's specific processes, including crossing non-diapause and diapause silkworm strains, gene introduction into F1 fertilized eggs, unfertilized egg collection from F1 female individuals, and parthenogenetic induction, are clearly defined in the patent claims. These steps can be implemented by applying existing silkworm rearing and genetic manipulation knowledge, suggesting relatively smooth technology adoption without extensive capital investment. The technical hurdles are considered manageable for companies with existing bio-research facilities.
Success Scenario
Upon adopting this technology, licensees could significantly enhance genetically modified silkworm production efficiency and establish a stable supply system for specific high-function proteins or biomaterials. This is estimated to reduce annual production costs by over ~$650K (AI est.) compared to conventional methods, accelerating new product development and strengthening market competitiveness. Consequently, it could enable companies to secure a dominant position in the pharmaceutical, functional food, and advanced material markets.
Patent Record
APPLICATION NO.
特願2024-052675
REGISTRATION NO.
7731605
FILING DATE
2024/03/28
GRANT DATE
2025/08/22
EXPIRATION DATE
2044/03/28
PATENT HOLDER
国立研究開発法人農業・食品産業技術総合研究機構
Examination History
2024年03月28日
出願審査請求書
2024年05月28日
手続補正書（自発・内容）
2025年03月11日
拒絶理由通知書
2025年07月01日
意見書
2025年08月05日
特許査定